HealthQuill China
The European Union approved AstraZeneca Plc and Amgen Inc.’s add-on therapy to treat adults with a chronic inflammatory condition of the nasal passages.
Drugs Health Pharma

AstraZeneca, Amgen’s drug for nasal inflammation gets EU nod

The European Union approved AstraZeneca Plc and Amgen Inc.’s add-on therapy to treat adults with a chronic inflammatory condition of the nasal passages.

Read More
China’s Innovent Biologics and Takeda Pharmaceutical Co. announced a $11.4 billion licensing deal, which will enable the former to speed up the development of its immuno-oncology and antibody-drug conjugate cancer therapies.
Drugs Health Pharma

China’s Innovent, Japan’s Takeda in $11.4 billion deal for cancer therapies

China’s Innovent Biologics and Takeda Pharmaceutical Co. announced a $11.4 billion licensing deal, which will enable the former to speed up the development.

Read More
Merck and Co. will invest up to $70 billion to expand its domestic manufacturing in the US after President Donald Trump urged pharmaceutical companies to set up their bases within the country and reduce reliance on imports of drugs.
Drugs Health Pharma

Merck to spend $70 billion to expand domestic manufacturing in US

Merck and Co. will invest up to $70 billion to expand its domestic manufacturing in the US after President Donald Trump urged pharmaceutical.

Read More
Zenas BioPharma, Inc. and China’s InnoCare Pharma Limited have inked a $2 billion licensing deal that grants the US-based Zenas global rights to develop and commercialise an investigational drug to treat multiple sclerosis (MS) and other autoimmune diseases.
Drugs Health Pharma

Zenas, InnoCare in $2b licensing deal for MS, autoimmune diseases

Zenas BioPharma, Inc. and China’s InnoCare Pharma Limited have inked a $2 billion licensing deal that grants the US-based Zenas global rights to.

Read More
https://www.novartis.com/research-and-development/research-disease-areas/cardiovascular-and-metabolic-disease-research-novartis
Drugs Health Pharma

Novartis signs $5.2 billion pact with China’s Argo Biopharmaceutical

HQ Team September 4, 2025: China’s Argo Biopharmaceutical Co., Ltd., and Switzerland’s Novartis AG have inked a $5.2 billion pact to develop new.

Read More
Britain’s GSK Plc will pay Jiangsu Hengrui Pharmaceuticals $500 million upfront to acquire global licensing rights for the Chinese company’s 12 potential medicines.
Drugs Health Pharma

GSK inks $500m deal with Jiangsu Hengrui for 12 potential medicines

HQ Team July 28, 2025: Britain’s GSK Plc will pay Jiangsu Hengrui Pharmaceuticals $500 million upfront to acquire global licensing rights for the.

Read More
The two hypothetical origins of the Covid-19 pandemic, namely the animal-to-human transmission and a laboratory leak, remain on the table as more information is needed to fully evaluate both, according to the World Health Organization.
Drugs Health Pharma

WHO says more information needed to track SARS-CoV-2 origins

HQ Team June 30, 2025: The two hypothetical origins of the Covid-19 pandemic, namely the animal-to-human transmission and a laboratory leak, remain on.

Read More
The US drug regulator has announced an immediate review of new clinical trials that involve sending American citizens’ living cells to China and other “hostile countries” for the fear of genetic data misuse.
Drugs Health Pharma

US to review trials to stop genetic data misuse by China, ‘hostile’ nations

HQ Team June 19, 2025: The US drug regulator has announced an immediate review of new clinical trials that involve sending American citizens’.

Read More
Pfizer Inc. will pay Basilea Pharmaceutica Ltd. $ 2.5 million as the Swiss biopharmaceutical company exceeded the sales threshold of its antifungal therapy in the Asia Pacific region, triggering a milestone payment.
Drugs Health Pharma

Sales surge triggers Pfizer’s $2.5 million milestone payment to Basilea

HQ Team June 5, 2025: Pfizer Inc. will pay Basilea Pharmaceutica Ltd. $ 2.5 million as the Swiss biopharmaceutical company exceeded the sales.

Read More
Regeneron Pharmaceuticals, Inc. will pay China’s Hansoh Pharmaceuticals Group Company Limited $80 million upfront to acquire rights for a weight-loss drug candidate.
Drugs Health Pharma

Regeneron to pay China’s Hansoh $80m upfront for weight-loss drug

HQ Team June 2, 2025: Regeneron Pharmaceuticals, Inc. will pay China’s Hansoh Pharmaceuticals Group Company Limited $80 million upfront to acquire rights for.

Read More